source
- HHS pushes FDA to formalize public release of rejection letters to drug makersHHS announced it is preparing a new FDA regulation that would codify the agency's practice of publishing complete response letters (CRLs) that inform pharmaceutical companies of a drug's rejection.…
- Biohaven targets muscle-sparing obesity market to compete with Lilly's GLP-1 drugsBiohaven is positioning itself to address obesity by developing treatments that preserve lean muscle, a differentiator from existing GLP-1 therapies. The company sees an opportunity to act as a "s…